Shares of Schrödinger, Inc. (NASDAQ:SDGR – Get Free Report) have received an average recommendation of “Buy” from the eight analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $32.29.
Several analysts have recently weighed in on SDGR shares. KeyCorp boosted their target price on Schrödinger from $25.00 to $27.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Piper Sandler reduced their price objective on Schrödinger from $50.00 to $45.00 and set an “overweight” rating for the company in a research note on Thursday. Finally, BMO Capital Markets upped their price objective on Schrödinger from $25.00 to $28.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th.
Check Out Our Latest Report on Schrödinger
Hedge Funds Weigh In On Schrödinger
Schrödinger Price Performance
Schrödinger stock opened at $22.31 on Friday. Schrödinger has a 1-year low of $16.67 and a 1-year high of $29.15. The stock has a market cap of $1.63 billion, a PE ratio of -9.53 and a beta of 1.61. The stock’s fifty day moving average is $22.34 and its two-hundred day moving average is $20.60.
Schrödinger (NASDAQ:SDGR – Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.20). Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. The firm had revenue of $88.32 million during the quarter, compared to analysts’ expectations of $83.20 million. On average, research analysts expect that Schrödinger will post -2.37 earnings per share for the current fiscal year.
Schrödinger Company Profile
Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.
Recommended Stories
- Five stocks we like better than Schrödinger
- P/E Ratio Calculation: How to Assess Stocks
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- What is diluted earnings per share (Diluted EPS)?
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- Investing In Preferred Stock vs. Common Stock
- MarketBeat Week in Review – 02/24 – 02/28
Receive News & Ratings for Schrödinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrödinger and related companies with MarketBeat.com's FREE daily email newsletter.